FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.23
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$31.76

30 Oct
2025

0.100

OPEN

$31.60

0.32%

HIGH

$32.14

483,830

LOW

$31.30

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 66.2 xxx
DPS (cps) 42.2 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 48.9 xxx
Dividend Yield 1.3% xxx
Div Pay Ratio(%) 63.8% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 2.08%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.15

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/12 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx58.6
DPS All xxxxxxxxxxxxxxx45.5
Sales/Revenue xxxxxxxxxxxxxxx1,842.0 M
Book Value Per Share xxxxxxxxxxxxxxx293.2
Net Operating Cash Flow xxxxxxxxxxxxxxx499.4 M
Net Profit Margin xxxxxxxxxxxxxxx18.64 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx20.62 %
Return on Invested Capital xxxxxxxxxxxxxxx19.75 %
Return on Assets xxxxxxxxxxxxxxx15.57 %
Return on Equity xxxxxxxxxxxxxxx20.62 %
Return on Total Capital xxxxxxxxxxxxxxx25.59 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx254.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx79 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx139 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx240 M
Price To Book Value xxxxxxxxxxxxxxx10.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx93.8 M
Capex % of Sales xxxxxxxxxxxxxxx5.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx683 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx693 M
Research & Development xxxxxxxxxxxxxxx207 M
Investments - Total xxxxxxxxxxxxxxx35 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

24/07/2025

3

Neutral

-

-

UBS details Fisher & Paykel Healthcare's Investor Day highlights, including the company's approach to altering clinical practice with better patient outcomes and lower hospital costs across four segments, including high flow therapy in the emergency department, ward, anaesthesia, and neonatal.

The broker notes Australian hospitals are using high flow therapy for the majority of anaesthesia operations to improve patient safety for longer intubation times and wider airway openings.

The growth in the therapy is increasingly reliant on hospital adoption for adult respiratory disorders in emergency and other wards, UBS states.

Neutral rating and NZ$37 target retained.

FORECAST
UBS forecasts a full year FY26 dividend of 44.51 cents and EPS of 68.13 cents.
UBS forecasts a full year FY27 dividend of 53.60 cents and EPS of 81.76 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

26/08/2025

3

Neutral

-

-

Fisher & Paykel Healthcare has issued a trading update with 1H26 revenue guidance of around NZ$1.075bn, up 13%, and profit guidance of around NZ$200m, up 31%.

Full-year FY26 guidance is unchanged at revenue of NZ$2.15bn–NZ$2.25bn and profit of NZ$390m–NZ$440m, compared with Jarden’s NZ$2.27bn and NZ$443m forecasts.

The broker notes retention of guidance implies a minor upgrade given weaker FX, with the tariff impact now -75bps versus -50bps, mostly weighted to 2H.

Hospital growth is likely ahead of Homecare in the first half, suggest the analysts, while growth rates are fading as the company cycles a strong prior period.

Neutral. Target unchanged at NZ$34.50.

FORECAST
Jarden forecasts a full year FY26 dividend of 44.51 cents and EPS of 68.50 cents.
Jarden forecasts a full year FY27 dividend of 50.87 cents and EPS of 77.94 cents.
Access Extra Coverage Research History >

FPH STOCK CHART

FNArena News on FPH

1
Rudi’s View: ALS, Bega, Coles, Elders, Light & Wonder, Lovisa, Telix & More

Oct 23 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
3
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Aug 26, 2025

Aug 26 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jul 29, 2025

Jul 29 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
2
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
3
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
4
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
5
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
6
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
7
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
8
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
9
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
10
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia